Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus

Metzler, Kelli; Hansen, Georg Nørgaard; Hedlin, Peter; Harding, Elizabeth; Drlica, Karl; Blondeau, Joseph M

doi:10.1016/j.ijantimicag.2004.02.021

Cited by 104 publications

(80 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, the MPC of CIP, determined for S. aureus MT5 at 0.9 g/ml after 2 days incubation (13), was well below the value reported in Table 1 and, most likely, attributable to the shorter incubation period. The MPC 90 of MXF was previously reported to be 0.25 g/ml for 122 methicillin-susceptible clinical isolates of S. aureus (30), and this value was similar to the MPC of PRA determined with S. aureus DSM 11823 (Table 2). In animals, drug levels required to achieve MPC conditions should readily be attained with PRA (19).…”

Section: Discussionsupporting

confidence: 84%

Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance

Wetzstein

2005

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 84%

Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance

Wetzstein

2005

Antimicrob Agents Chemother

View full text Add to dashboard Cite

“…However, at designated time points, there were no significant differences in the percentage of intracellular clarithromycin in bacteria treated with liposomal clarithromycin only, or the co-delivery liposomal system (Supplementary Figure 2). Alternatively, the mutant selection window (MSW) hypothesis may be used to explain the synergy of multiple antibiotics with different bactericidal mechanisms, and measurement of the MPC can indicate whether an antibiotic should be used alone or in combination with others (Dong et al, 1999;Zhao & Drlica, 2002;Metzler et al, 2004). The MPC and MSW (defined by determination of MIC 99 and MPC) of different liposomal formulations against MRSA were determined in the present study.…”

Section: Discussionmentioning

confidence: 97%

“…The mutant prevention concentration (MPC) of the free drugs and their liposomal formulations were determined by the agar diffusion test (Dong et al, 1999;Zhao & Drlica, 2002;Metzler et al, 2004). Approximately 410 10 CFU/mL bacteria were spread onto Mueller-Hinton agar plates (MH IIA) containing different formulations, incubated at 37 C for 72 h, and the colony numbers were counted at 24 h intervals until they became constant.…”

Section: Determination Of the Mutant Prevention Concentrationmentioning

confidence: 99%

Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistantStaphylococcus aureusinfection

Zhang

et al. 2014

Drug Delivery

View full text Add to dashboard Cite

(2015) Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistant Staphylococcusaureus infection, Drug Delivery, 22:5, 627-637, DOI: 10.3109/10717544.2014 CD]) at an optimized mass ratio of 1:32 were generated and characterized using dynamic light scattering and electron microscopy. In vitro and in vivo approaches were used to compare liposome effects on MRSA. Results: PL[CD] were stable, with a mean (±SD) vesicle diameter of 98.2 ± 2.21 nm and encapsulation efficiency of 94.71 ± 1.37% (daptomycin) and 92.94 ± 1.21% (clarithromycin). Compared with daptomycin-only liposomes, PL [CD] showed significantly enhanced anti-MRSA activity in vitro and significantly reduced MRSA bacterial load and increased host survival in vivo. Discussion: Co-delivery of daptomycin with clarithromycin produced significant anti-MRSA activity in the presence of only one-thirtieth of the concentration required in liposomes containing daptomycin only. Conclusion: These findings suggested that concurrent liposomal delivery of daptomycin and clarithromycin has the potential to be an effective and less toxic treatment for MRSA infections.

show abstract

“…The successful use of ciprofloxacin or ofloxacin alone (13,21,25) or in combination (8) for treatment of S. aureus skeletal infections has been described. Moxifloxacin exhibits enhanced activity against S. aureus (16, 19), has a low propensity to select in vitro and in vivo resistant mutants (1,11,18,21,25), and diffuses well in synovial fluid (SF) (6). One paper has reported the successful use of moxifloxacin in bone and joint infections in the clinical setting (12).…”

mentioning

confidence: 99%

“…Moxifloxacin could be preferred in this clinical setting. Indeed, studies have shown the lower propensity of moxifloxacin to select resistant mutants in vitro and in vivo among staphylococci (1,18,21,25) and its activity against first-level ciprofloxacin-resistant MRSA strains, with a MIC of 0.25 g/ml (10). Frippiat et al recently reported favorable outcomes with moxifloxacin in association with rifampin in seven clinical cases of staphylococcal bone and joint infections (12).…”

mentioning

confidence: 99%

In Vivo Efficacy of Moxifloxacin Compared with Cloxacillin and Vancomycin in a Staphylococcus aureus Rabbit Arthritis Experimental Model

Grossi

Caillon

Arvieux

et al. 2007

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We investigated the efficacies of moxifloxacin, cloxacillin, and vancomycin in a rabbit model of Staphylococcus aureus arthritis. No significant difference between therapeutic regimens was observed after a 7-day treatment. Oral moxifloxacin could be a suitable alternative to standard parenteral therapy for S. aureus arthritis.Nongonococcal acute septic arthritis remains a leading cause of destructive joint disease (14,26). Treatment includes both drainage of the infected joint and antibiotic therapy. Staphylococcus aureus is the pathogen most often involved in bacterial arthritis (9,14,26). Therapy consists of intravenous penicillinase-resistant penicillin or vancomycin for 1 or 2 weeks. A switch to oral therapy is typical following clinical improvement (4). The successful use of ciprofloxacin or ofloxacin alone (13,21,25) or in combination (8) for treatment of S. aureus skeletal infections has been described. Moxifloxacin exhibits enhanced activity against S. aureus (16, 19), has a low propensity to select in vitro and in vivo resistant mutants (1,11,18,21,25), and diffuses well in synovial fluid (SF) (6). One paper has reported the successful use of moxifloxacin in bone and joint infections in the clinical setting (12). The aim of this study was to evaluate the in vivo efficacy of moxifloxacin in comparison with cloxacillin and vancomycin in a rabbit arthritis model induced with methicillin-susceptible and -resistant S. aureus (MSSA and MRSA, respectively) strains.Two quinolone-susceptible S. aureus strains were studied. One clinical isolate from a case of acute arthritis was an MSSA strain, and the other, isolated from blood culture, was methicillin resistant (MRSA).The MICs of moxifloxacin and vancomycin were determined by microdilution in Mueller-Hinton broth (2, 24). The MICs of cloxacillin were determined by the same method, but with Mueller-Hinton broth containing 2% NaCl (22).Rabbit arthritis was induced by injection of 1 ml of a 10 8 -CFU inoculum of MSSA or MRSA into the joint space of the right knee (17). Animals infected with MSSA were randomly assigned to the moxifloxacin or cloxacillin group, and those infected with MRSA were randomly assigned to the moxifloxacin or vancomycin group. A control group without treatment was also constituted to ensure that the lowering of the bacterial concentration was not because of an immunologic response.The treatments were started 24 h after bacterial challenge, and all animals were treated for 7 days. A computer controlled the flow rate of moxifloxacin in order to simulate a human oral dose of 400 mg daily (5). Vancomycin was administered by a constant intravenous infusion and allowed to reach a 20-mg/ liter serum steady-state concentration (dose of 100 mg/kg of body weight daily). Cloxacillin was injected via the intramuscular route at a dose leading to supra-MIC levels in serum (50 mg/kg three times a day) (7). Before treatment, an SF sample (SF 1) was taken from each infected rabbit knee. At the end of the treatment, all of the SF (SF 2) was removed from each...

show abstract

Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus

Cited by 104 publications

References 37 publications

Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance

Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance

Liposomal co-delivery of daptomycin and clarithromycin at an optimized ratio for treatment of methicillin-resistantStaphylococcus aureusinfection

In Vivo Efficacy of Moxifloxacin Compared with Cloxacillin and Vancomycin in a Staphylococcus aureus Rabbit Arthritis Experimental Model

Contact Info

Product

Resources

About